<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332369</url>
  </required_header>
  <id_info>
    <org_study_id>EyeKon CTR--01</org_study_id>
    <nct_id>NCT02332369</nct_id>
  </id_info>
  <brief_title>EyeKon Medical Inc. Capsular Tension Ring Study</brief_title>
  <acronym>CTR</acronym>
  <official_title>EyeKon Medical, Inc. Capsular Tension Ring Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EyeKon Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EyeKon Medical, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and effectiveness of a capsular tension ring (CTR) when used&#xD;
      during cataract surgery. Capsular Tension Rings are used during intraocular lens implantation&#xD;
      to give added support in order to keep the intraocular lens well centered, especially in eyes&#xD;
      with weak or partially absent zonules. In many cases, capsular tension rings allow a lens to&#xD;
      be successfully implanted into an eye which otherwise could not have supported an intraocular&#xD;
      lens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical study of the CTR-10 and CTR-12 Capsular Tension Rings is to be conducted with&#xD;
      the following objectives:&#xD;
&#xD;
        1. Determine the ability of the device to maintain the shape of the capsular bag and&#xD;
           therefore keep the intraocular lens centered;&#xD;
&#xD;
        2. Determine post-operative visual acuity of patients receiving the capsular tension ring&#xD;
           as a secondary method of determining the efficacy;&#xD;
&#xD;
        3. Describe the occurrence and time course of postoperative complications and adverse&#xD;
           reactions for capsular tension ring implant subjects;&#xD;
&#xD;
        4. Describe the occurrence of postoperative complications for the implant group and their&#xD;
           relationship to ocular complications.&#xD;
&#xD;
        5. Identify groups within the implant study population that are at &quot;high risk&quot; of&#xD;
           particular complications.&#xD;
&#xD;
        6. Collect and analyze against those historical controls published by FDA data on:&#xD;
&#xD;
             1. Overall Visual Acuity&#xD;
&#xD;
             2. Best Case Visual Acuity&#xD;
&#xD;
             3. Cumulative Hyphema&#xD;
&#xD;
             4. Cumulative Macular Edema&#xD;
&#xD;
             5. Cumulative Retinal Detachment&#xD;
&#xD;
             6. Cumulative Pupillary Block&#xD;
&#xD;
             7. Cumulative Lens Dislocation&#xD;
&#xD;
             8. Cumulative Endophthalmitis&#xD;
&#xD;
             9. Cumulative Hypopyon&#xD;
&#xD;
            10. Cumulative Surgical Reintervention&#xD;
&#xD;
            11. Persistent Macular Edema&#xD;
&#xD;
            12. Persistent Corneal Edema&#xD;
&#xD;
            13. Persistent Iritis&#xD;
&#xD;
            14. Persistent Raised IOP Requiring treatment&#xD;
&#xD;
            15. Frequency and degree of posterior capsule opacification&#xD;
&#xD;
      The investigational plan for the clinical study of capsular tension rings is designed to&#xD;
      satisfy the requirements of the Investigational Device Exemption (IDE) regulations, which&#xD;
      require a well-controlled clinical trial with ongoing monitoring to evaluate the safety and&#xD;
      efficacy of the intraocular lenses.&#xD;
&#xD;
      The study will consist of adult patients who will be enrolled into the study. The results of&#xD;
      these implants will be carefully monitored for approximately twelve (12) months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2005</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>At all pre/post op CFR's for 1 year.</time_frame>
    <description>Best case visual acuity at 1 year of follow-up based upon LogMar score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 Year</time_frame>
    <description>Adverse events will be compared to the FDA historical grid and must be less than or equal to those shown in the grid on a percentage of patients enrolled basis.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Cataract Extraction</condition>
  <arm_group>
    <arm_group_label>Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polymethylmethacrylate Capsular Tension Ring introduced into the posterior chamber of the eye following cataract surgery before the implantation of an intraocular lens.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Capsular Tension Ring</intervention_name>
    <arm_group_label>Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient is in good general and ocular health, having a vision-reducing cataract in&#xD;
             the intended operative eye.&#xD;
&#xD;
          -  The intended operative eye has a Snellen best corrected visual of 20/40 or worse for&#xD;
             distance or the refraction worsens to this level with glare testing.&#xD;
&#xD;
          -  The patients' worse seeing Eye is 20/70 or better.&#xD;
&#xD;
          -  The patient is willing and able to complete all required postoperative visits.&#xD;
&#xD;
          -  The patient is willing to sign a statement of informed consent.&#xD;
&#xD;
          -  The patient is at least 21 years old.&#xD;
&#xD;
          -  The patient requires cataract surgery with IOL implantation.&#xD;
&#xD;
          -  The patient has observed or suspected weakened, torn, missing or otherwise compromised&#xD;
             zonules (torn or missing estimated not to exceed one-third of the capsular bag&#xD;
             diameter) due to Pseudoexfoliation Syndrome, Marfans Syndrome, trauma or other zonular&#xD;
             compromising condition.&#xD;
&#xD;
          -  The capsule is intact during insertion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Only one functional eye&#xD;
&#xD;
          -  Capsular bag tearing beyond the point where the surgeon thinks it is in the best&#xD;
             interest of the patient to have a capsular ring implanted&#xD;
&#xD;
          -  Significant zonular didlysis during surgery&#xD;
&#xD;
          -  Preoperative ocular infection&#xD;
&#xD;
          -  Ocular inflammation or uveitis&#xD;
&#xD;
          -  Amblyopia&#xD;
&#xD;
          -  Aniridia&#xD;
&#xD;
          -  Congenital cataracts&#xD;
&#xD;
          -  Cataracts due to rubella&#xD;
&#xD;
          -  Corneal disease&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Preoperative intraocular pressure over 21 mm Hg&#xD;
&#xD;
          -  Iritis&#xD;
&#xD;
          -  Iris atrophy&#xD;
&#xD;
          -  Pseudophakic lens exchange&#xD;
&#xD;
          -  Microphthalmia&#xD;
&#xD;
          -  Optic atrophy&#xD;
&#xD;
          -  Macular degeneration&#xD;
&#xD;
          -  Retinal detachment&#xD;
&#xD;
          -  Retinal degeneration&#xD;
&#xD;
          -  Vitritis&#xD;
&#xD;
          -  Flat anterior chamber&#xD;
&#xD;
          -  Other conditions as noted by the surgeon which may compromise the safety of the&#xD;
             patient or the accuracy of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Robinson</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor/CEO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barry L Bowyer, MSPH</last_name>
    <phone>7277930170</phone>
    <email>barry@eyekonmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Robinson</last_name>
    <phone>7277930170</phone>
    <email>Mark@eyekonmedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stephenson Eye Associates</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <zip>34285</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Eye Care Ltd.</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Brazosport Eye Institute</name>
      <address>
        <city>Lake Jackson</city>
        <state>Texas</state>
        <zip>77566</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Penland</last_name>
      <email>ljm.christianp@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jonathan Grady, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>January 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2015</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

